• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare.

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508606323/en/

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare.

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare.

    Elshenawy brings over two decades of experience in the technology sector to Hims & Hers, leading large scale AI, product, and engineering teams across mobility, e-commerce, and cloud. Most recently as the President and CTO at Cruise, a self-driving vehicle company owned by General Motors, Mo led the organization through critical phases across regulatory, operations and technical development to launch and scale the first commercial driverless rideshare service in San Francisco. He has also held senior leadership roles at Amazon, where he led global engineering for the company's ReCommerce business and led the creation of retail data analytics platforms that powered over hundreds of millions in revenue. He holds more than 10 patents across AI, robotics, and autonomous vehicles.

    "The future of care connects diagnosis, treatment, and delivery seamlessly, and in a way that feels tailored to the individual. We believe AI is an important way to standardize high-quality care globally to millions of people, regardless of their income or where they live," said Andrew Dudum, CEO and co-founder of Hims & Hers. "Our ambition to build a platform that offers access to safe, high-quality personalized care requires an accelerated investment in technology, and Mo is just the leader to drive that work."

    "We are standing at the edge of a healthcare revolution, and Hims & Hers is uniquely positioned to lead it," said Elshenawy. "By harnessing the transformative power of AI and data, we can reimagine how care is delivered—making it more intelligent, more personal, and radically more accessible. I'm honored to join a team that shares this bold vision and is building a next-generation platform designed to serve millions with the precision and empathy every person deserves."

    Hims & Hers is transforming how everyone can improve and manage their long-term health, by delivering a seamless and smart end-to-end experience from intake to diagnosis to treatment and beyond. Beyond expanding the scope and precision of MedMatch and its intelligent routing system, Hims & Hers will invest in AI to improve diagnosis and elevate the health and wellness experience. Elshenawy's appointment comes as the company advances its long-term vision to build a modern healthcare platform, powered by AI and direct-to-consumer infrastructure. Hims & Hers is working to modernize a system that has long struggled to keep pace with demand, aiming to make care more accessible, affordable, and responsive to the evolving needs of millions. By further investing in technology and continuing to innovate across diagnostic tools, personalized treatments, data-rich integrations, and elevated customer experience, the company believes it can dramatically increase access to world-class, personalized care.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508606323/en/

    Press Contact

    Abby Reisinger-Moley

    [email protected]

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    More analyst ratings

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hims & Hers Health downgraded by Needham

      Needham downgraded Hims & Hers Health from Buy to Hold

      6/23/25 11:43:05 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Needham reiterated coverage on Hims & Hers Health with a new price target

      Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

      6/4/25 7:59:55 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

      Unlocking a New Dimension of Personalized Digital Healthcare for Millions Across Europe Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims

      6/3/25 7:15:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Introduces 6-Month Wegovy® New Customer Offer

      Hims & Hers Health, Inc. (NYSE:HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522903885/en/Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only). "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of

      5/22/25 3:39:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care